A critical role for immune system response in mediating anti-influenza drug synergies assessed by mechanistic modeling

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 9, 2014, Pages

  Li, Z ^a   Zhou, H ^a   Lu, Y ^a   Colatsky, T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ARTICLE; COMPUTER MODEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INNATE IMMUNITY; MONOTHERAPY; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84927946806     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.32     Document Type: Article

References (49)

1. Saenz, R.A. et al. Dynamics of influenza virus infection and pathology. J. Virol. 84, 3974-3983 (2010).
2. Simonsen, L., Clarke, M.J., Williamson, G.D., Stroup, D.F., Arden, N.H. & Schonberger, L.B. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health 87, 1944-1950 (1997).
3. Chizhmakov, I.V., Geraghty, F.M., Ogden, D.C., Hayhurst, A., Antoniou, M. & Hay, A.J. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J. Physiol. 494 (Pt 2), 329-336 (1996).
4. Garman, E. & Laver, G. Controlling influenza by inhibiting the virus's neuraminidase. Curr. Drug Targets 5, 119-136 (2004).
5. Reuman, P.D., Bernstein, D.I., Keefer, M.C., Young, E.C., Sherwood, J.R. & Schiff, G.M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 11, 27-40 (1989).
6. Treanor, J.J. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283, 1016-1024 (2000).
7. Nguyen, J.T. et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5, e9332 (2010).
8. van der Vries, E., van den Berg, B. & Schutten, M. Fatal oseltamivir-resistant influenza virus infection. N. Engl. J. Med. 359, 1074-1076 (2008).
9. Gulick, R.M. et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280, 35-41 (1998).
10. Greco, W.R., Bravo, G. & Parsons, J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
11. Nguyen, J.T. et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53, 4115-4126 (2009).
12. Ilyushina, N.A., Hoffmann, E., Salomon, R., Webster, R.G. & Govorkova, E.A. Amantadineoseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12, 363-370 (2007).
13. Mestas, J. & Hughes, C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
14. Dixit, N.M., Layden-Almer, J.E., Layden, T.J. & Perelson, A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922-924 (2004).
15. Beauchemin, C.A. & Handel, A. A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11 (suppl. 1), S7 (2011).
16. Lee, H.Y. et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. J. Virol. 83, 7151-7165 (2009).
17. Pawelek, K.A., Huynh, G.T., Quinlivan, M., Cullinane, A., Rong, L. & Perelson, A.S. Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput. Biol. 8, e1002588 (2012).
18. Baccam, P., Beauchemin, C., Macken, C.A., Hayden, F.G. & Perelson, A.S. Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599 (2006).
19. Davies, B.E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65 (suppl. 2), ii5-ii10 (2010).
20. Wattanagoon, Y. et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob. Agents Chemother. 53, 945-952 (2009).
21. Morimoto, K. et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. J. Pharm. Sci. 100, 3854-3861 (2011).
22. Aoki, F.Y. & Sitar, D.S. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14, 35-51 (1988).
23. Bleidner, W.E., Harmon, J.B., Hewes, W.E., Lynes, T.E. & Hermann, E.C. Absorption, distribution and excretion of amantadine hydrochloride. J. Pharmacol. Exp. Ther. 150, 484-490 (1965).
24. Horadam, V.W. et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann. Intern. Med. 94, 454-458 (1981).
25. Morrison, D. et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One 2, e1305 (2007).
26. Hayden, F.G., Fritz, R., Lobo, M.C., Alvord, W., Strober, W. & Straus, S.E. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101, 643-649 (1998).
27. Gazit, R. et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7, 517-523 (2006).
28. Grundy, J.E., Trapman, J., Allan, J.E., Shellam, G.R. & Melief, C.J. Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect. Immun. 37, 143-150 (1982).
29. Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H. & Schreiber, R.D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
30. Yoon, H., Legge, K.L., Sung, S.S. & Braciale, T.J. Sequential activation of CD8+ T cells in the draining lymph nodes in response to pulmonary virus infection. J. Immunol. 179, 391-399 (2007).
31. Miao, H. et al. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 84, 6687-6698 (2010).
32. Polakos, N.K. et al. Early intrahepatic accumulation of CD8+ T cells provides a source of effectors for nonhepatic immune responses. J. Immunol. 179, 201-210 (2007).
33. Hamilton-Easton, A. & Eichelberger, M. Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J. Virol. 69, 6359-6366 (1995).
34. Siegal, F.P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835-1837 (1999).
35. Smed-Sörensen, A. et al. Influenza A virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells. PLoS Pathog. 8, e1002572 (2012).
36. Foster, G.R., Germain, C., Jones, M., Lechler, R.I. & Lombardi, G. Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactions. Eur. J. Immunol. 30, 3228-3235 (2000).
37. Knight, V., Fedson, D., Baldini, J., Douglas, R.G. & Couch, R.B. Amantadine therapy of epidemic influenza a(2) (Hong Kong). Infect. Immun. 1, 200-204 (1970).
38. van den Brand, J.M. et al. Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic avian influenza H5N1 virus infections in ferrets. PLoS One 7, e42343 (2012).
39. Guarner, J. et al. Immunohistochemical and in situ hybridization studies of influenza A virus infection in human lungs. Am. J. Clin. Pathol. 114, 227-233 (2000).
40. White, N.J., Webster, R.G., Govorkova, E.A. & Uyeki, T.M. What is the optimal therapy for patients with H5N1 influenza? PLoS Med. 6, e1000091 (2009).
41. Nguyen, J.T. et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 7, e31006 (2012).
42. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009).
43. Owens, C.M. et al. Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol. Syst. Biol. 6, 375 (2010).
44. Saito, R. et al. A travel guide to Cytoscape plugins. Nat. Methods 9, 1069-1076 (2012).
45. Vermaelen, K. & Pauwels, R. Pulmonary dendritic cells. Am. J. Respir. Crit. Care Med. 172, 530-551 (2005).
46. Zambon, M. & Hayden, F.G.; Global Neuraminidase Inhibitor Susceptibility Network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49, 147-156 (2001).
47. Prichard, M.N. & Shipman, C. Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14, 181-205 (1990).
48. Jhee, S.S. et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob. Agents Chemother. 52, 3687-3693 (2008).
49. Hayden, F.G., Minocha, A., Spyker, D.A. & Hoffman, H.E. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. 28, 216-221 (1985).